Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT05559359

Public ClinicalTrials.gov record NCT05559359. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).

Study identification

NCT ID
NCT05559359
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
377 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Months to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 17, 2022
Primary completion
Jan 13, 2026
Completion
Nov 30, 2026
Last update posted
Jul 29, 2026

2022 – 2026

United States locations

U.S. sites
21
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
Clinical Research Center of Alabama Birmingham Alabama 35209
Phoenix Children's Hospital Phoenix Arizona 85016
Arkansas Research Trials North Little Rock Arkansas 72217
First OC Dermatology Fountain Valley California 92708
Antelope Valley Clinical Trials Lancaster California 93534
Dermatology Research Associates Los Angeles California 90045
Integrative Skin Science and Research Sacramento California 95815
Rady's Children Hospital San Diego - Dermatology San Diego California 92123
UConn Health Farmington Connecticut 06030-2840
Solutions Through Advanced Research Jacksonville Florida 32256
ForCare Clinical Research Tampa Florida 33613
Treasure Valley Medical Research Boise Idaho 83706
Northwestern University Chicago Illinois 60611
Allergy & Asthma Specialists, P.S.C. Owensboro Kentucky 42301
Respiratory Medicine Research Institute of Michigan, PLC Ypsilanti Michigan 48197
Dartmouth-Hitchcock Medical Center Lebanon New Hampshire 03766
Psoriasis Treatment Center of Central New Jersey East Windsor New Jersey 08520
Dermatologists of Central States, LLC Fairborn Ohio 45324
Medical University of South Carolina Charleston South Carolina 29425
Texas Dermatology and Laser Specialists San Antonio Texas 78218
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05559359, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 29, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05559359 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →